Latest Tenofovir Stories
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum.
Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, supporting the use of this drug during pregnancy.
An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.
Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research.
A gel formulation of the antiretroviral drug tenofovir designed specifically for rectal use was found safe and acceptable.
New research from the University of North Carolina at Chapel Hill schools of medicine and pharmacy may help explain the failure of some recent clinical trials of prevention of HIV infection, compared to the success of others that used the same drugs.
VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women – daily use of one of two different ARV tablets or of a vaginal gel – will be dropping the vaginal gel from the study.
A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants.
- an ornament or knob in the shape of a flower